rivoceranib
-
HLB to Merge with HLB Life Science for Greater Efficiency and ValueBig Tech 2025. 4. 2. 01:53
· HLB merges with HLB Life Science to enhance efficiency and maximize value. HLB has announced its merger with its subsidiary, HLB Life Science, to simplify its corporate structure, enhance management efficiency, and maximize shareholder value. The boards of both companies approved the merger on April 1, with HLB issuing new shares to HLB Life Science shareholders at a predetermined exchange rat..
-
HLB Holds 40th Annual General MeetingBig Tech 2025. 3. 31. 13:30
· Company reaffirms commitment to FDA approval for liver cancer drug On March 31, HLB held its 40th Annual General Meeting (AGM) at the Daejeon Convention Center, followed by an investor relations (IR) briefing and a shareholder meeting. During the AGM, Chairman Jin Yang-gon reaffirmed the company’s commitment to securing U.S. Food and Drug Administration (FDA) approval for its liver cancer drug..
-
US FDA Rejects HLB’s Liver Cancer Drug for the Second TimeBig Tech 2025. 3. 21. 13:40
· FDA issues Complete Response Letter for HLB’s liver cancer drug. The U.S. Food and Drug Administration (FDA) has issued a second Complete Response Letter (CRL) to HLB, a South Korean biopharmaceutical company, regarding its New Drug Application (NDA) for a liver cancer treatment. The decision, announced by HLB Chairman Jin Yang-gon, centers on unresolved issues related to the manufacturing pro..
-
HLB's Liver Cancer Drug Listed as First-Line Treatment in ESMO Guidelines Ahead of FDA ApprovalBig Tech 2025. 2. 27. 12:42
· ESMO strongly recommends rivoceranib and camrelizumab as a first-line treatment for liver cancer. SEOUL, South Korea, February 27, 2025 (IT Times) – HLB announced that its liver cancer treatment, rivoceranib and camrelizumab, has been listed as a first-line treatment in the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis and treatment of hepatocellul..
-
HLB’s Rivoceranib Gains Attention as a New Treatment Option for Adenoid Cystic CarcinomaBig Tech 2025. 2. 12. 17:12
· No standard treatment for ACC, rivoceranib shows promise · Expanding treatment options for rare cancers SEOUL, South Korea, February 12, 2025 (IT Times) - HLB's anti-ancer drug Rivoceranib, currently under development as a treatment for liver cancer, is emerging as a promising new option for adenoid cystic carcinoma (ACC), a rare cancer with significant unmet medical needs. The company, throug..
-
HLB Completes FDA’s CMC Inspection for Liver Cancer Drug ApprovalBig Tech 2025. 1. 15. 00:18
· Jiangsu Hengrui received three minor improvement requests from the FDA SEOUL, South Korea, January 14, 2025 (IT Times) - HLB, a leading biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has completed the Chemistry, Manufacturing, and Controls (CMC) inspection required for its liver cancer drug approval. The CMC inspection, conducted earlier this month,..
-
HLB Presents Promising Interim Results of Rivoceranib at ESMO 2024Big Tech 2024. 9. 20. 02:24
· HLB's rivoceranib combination therapies show potential for expanded indications. SEOUL, South Korea, September 19, 2024 (IT Times) - HLB, a leading biopharmaceutical company, today announced that its subsidiary Eleva Therapeutics and its partner, Jiangsu Hengrui Pharmaceuticals, presented 11 study results related to rivoceranib at the European Society for Medical Oncology (ESMO) Congress 2024 ..
-
HLB bioStep Unveils Global Expansion PlansBig Tech 2024. 6. 18. 10:34
· HLB bioStep is aggressively expanding globally leveraging its technology, experience and recent acquisition. HLB bioStep, a Korean non-clinical CRO (contract research organization), has announced its plans for aggressive global expansion. The company aims to leverage its world-class technology and infrastructure to achieve sustainable growth in the non-clinical CRO market. IT Times : https://w..
-
ASCO 2024: HLB's Rivoceranib Plus Camrelizumab Attracts a Liver Cancer Experts카테고리 없음 2024. 6. 4. 11:14
· Liver cancer experts are impressed by the rivoceranib plus camrelizumab combination's efficacy, minimal side effects, and potential to improve patient quality of life. SEOUL, South Korea, June 4, 2024 (IT Times) - HLB, a leading biopharmaceutical company, is making waves at the American Society of Clinical Oncology (ASCO) annual meeting. For the third year in a row, HLB's US subsidiary, Elevar..
-
HLB Announces Liver Cancer Treatment Results at ASCOBig Tech 2024. 6. 3. 16:47
· HLB's US subsidiary Elevar Therapeutics announced the updated Phase 3 CARES-310 study for uHCC at ASCO 2024. SEOUL, South Korea, June 3, 2024 (IT Times) - HLB, a leading biopharmaceutical company, today announced that the updated Phase 3 CARES-310 study evaluating a novel combination therapy with rivoceranib in unresectable hepatocellular carcinoma (uHCC) was presented as a poster at the Ameri..